Whitehawk Therapeutics Inc. Common Stock (WHWK)
Stock · NASDAQ · Health Care
$2.87as of 10/16/2026
Price chart
Active signals
WHWK Signal Track Record
How signals performed across all stocks →What WHWK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +1.1% | 56% | September 10, 2026 |
| Bollinger Band Breakout | 26 | -1.3% | 42% | August 4, 2026 |
| Bollinger Band BreakdownActive now | 14 | -8.0% | 36% | October 7, 2026 |
| Any 20-session window (baseline) | +0.6% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About WHWK
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 32
- Website
- ir.whitehawktx.com/
Fundamentals
- 1-day range
- $2.87$3.03
- Market cap
- $252.78M
- P/E (trailing)
- —
- P/E (forward)
- -2.93
- EPS (trailing)
- $-3.03
- Dividend yield
- —
- Beta
- 0.98
- Avg. volume
- 364.0K
How Whitehawk Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Whitehawk Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- MGNXMacroGenics Inc. Common Stock$3.25▼ 3.56%Market cap $254.89MP/E —$1.29$5.08
- AKBAAkebia Therapeutics Inc. Common Stock$0.67▼ 3.74%Market cap $256.03MP/E —$0.7$3.2
- RNACCartesian Therapeutics Inc. Common Stock$6.27▼ 4.71%Market cap $257.38MP/E —$5.6$11
- SLGLSol-Gel Technologies Ltd. Ordinary Shares$64.25▼ 6.48%Market cap $244.18MP/E —$28.81$97.97
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- CAPRCapricor Therapeutics Inc. Common Stock$6.71▼ 7.70%Market cap $242.07MP/E —$2.96$40.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| MGNX MacroGenics Inc. Common Stock | $254.89M | — | $3.25 | ▼ 3.56% | $1.29$5.08 |
| AKBA Akebia Therapeutics Inc. Common Stock | $256.03M | — | $0.67 | ▼ 3.74% | $0.7$3.2 |
| RNAC Cartesian Therapeutics Inc. Common Stock | $257.38M | — | $6.27 | ▼ 4.71% | $5.6$11 |
| SLGL Sol-Gel Technologies Ltd. Ordinary Shares | $244.18M | — | $64.25 | ▼ 6.48% | $28.81$97.97 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| CAPR Capricor Therapeutics Inc. Common Stock | $242.07M | — | $6.71 | ▼ 7.70% | $2.96$40.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug DevelopmentYahoo · 10/7/2026
- Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16benzinga · 10/1/2026
- Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026Yahoo · 10/1/2026
- Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16Benzinga · 10/1/2026
- Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9Benzinga · 10/1/2026
- Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLCBenzinga · 9/14/2026
- Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026Yahoo · 9/14/2026
Insider Activity
Insider Actions →- Lennon David James · September 15, 2026 · Grant194.0K
- Margaret Dugan · September 15, 2026 · Grant81.3K
- Dornan David · September 15, 2026 · Grant85.9K
- BALL BRYAN · September 15, 2026 · Grant91.6K
- Giacobello Scott M. · September 15, 2026 · Grant118.5K
- Iyengar Vijay K · September 9, 2026 · Grant76.1K
- Dalal Anupam · June 12, 2026 · Grant38.0K
- Zhao Baiteng · June 12, 2026 · Grant38.0K
- Desai Neil · June 12, 2026 · Grant38.0K
- Avoro Capital Advisors LLC · June 12, 2026 · Grant38.0K
- Reeve Emma · June 12, 2026 · Grant38.0K
- Hirmand Mohammad · June 12, 2026 · Grant38.0K
- Maroun Richard E · June 12, 2026 · Grant38.0K
- Castelein Caley · June 12, 2026 · Grant38.0K
- Dalal Anupam · May 14, 2026 · Grant1.28M @ $3.92
Institutional Ownership
March 31, 2026
- Total shares held
- 34.03M
- Total value held
- $118.39M
- Institutional holders
- 59
- Unknown4.62M
- Unknown4.17M
- Unknown3.70M
- Unknown3.41M
- Unknown2.85M
- Unknown2.17M
- Unknown2.08M
- Unknown2.07M
- Unknown1.32M
- Unknown1.14M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Whitehawk Shares Real-World Mucin 16 Data; Stifel Adds Coverage
Whitehawk Therapeutics presented two real‑world studies that support its Mucin‑16 platform. In the same week, Stifel began coverage and set a $9 price target. The company’s current price sits below that target, and the stock is near a key support level at $3.99. These developments add new information for investors to consider.
Whitehawk Shares Real-World Mucin 16 Data; Stifel Adds Coverage. Whitehawk Therapeutics presented two real‑world studies that support its Mucin‑16 platform. In the same week, Stifel began coverage and set a $9 price target. The company’s current price sits below that target, and the stock is near a key support level at $3.99. These developments add new information for investors to consider.